On May 21, the medical device sector started low. In the afternoon trading, United Imaging Healthcare surged 12%, Hotgen Biotech and Yirui Technology rose over 8%, Jiuan Medical, Xinmai Medical, and Ruimaite increased over 5%, while multiple stocks like Shanwaishan, Sino Medical, and Chunli Medical also rallied. The medical device ETF China Merchants (159898) rose 2.51%.
<img src="https://imageproxy.pbkrs.com/https://tongbi-app.oss-cn-shanghai.aliyuncs.com/word/media/3df781cd96fa40a6ab173f47537994f8.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://tongbi-app.oss-cn-shanghai.aliyuncs.com/word/media/3df781cd96fa40a6ab173f47537994f8.png"/>
On May 21, the National Medical Products Administration announced the review results of special applications for innovative medical devices, with 3 products entering the innovation channel. According to Guosen Securities, as of the end of April, the number of products approved by the National Medical Products Administration in the list of innovative medical devices has increased to 420.
The special review and priority approval procedures for innovative medical devices are referred to as the &#34;green channel&#34; for the approval of innovative products in the industry, which is a core policy measure in China to encourage medical device innovation and accelerate the market launch of clinically needed products. According to regulations, products entering the &#34;green channel&#34; can receive priority processing during registration, effectively shortening the registration cycle and allowing products to enter the fast track for approval and market launch.
With policy dividends and fundamental improvements, the medical device sector has entered a critical phase from valuation repair to performance growth, and the industry anticipates that it will attract funds flowing back from high-position technology sectors to low-position sectors.
According to Zhongtai Securities, the revenue of listed medical device companies is expected to reach 256.577 billion yuan in 2025, a year-on-year decrease of 1.42%, with a non-recurring net profit of 23.693 billion yuan, a year-on-year decrease of 15.16%. Negative disturbances are gradually clearing, and a stabilization and rebound is expected in 2026. Chengtong Securities also believes that the medical device industry is likely to welcome a performance inflection point in 2026.
Huaxin Securities pointed out that with high cost-performance advantages, exports have become the main breakthrough for the medical device industry to overcome internal competition and gain incremental growth. In Q1 2026, medical device exports amounted to 12.585 billion USD, a year-on-year increase of 8.92%. The medical device industry is an integrated multidisciplinary field, combining disciplines such as optoelectronic materials. Some medical device companies master core technologies in upstream optics and materials science, allowing them to develop not only medical products but also non-medical products. Expanding beyond traditional medical fields and seeking innovation has become one of the pathways for medical device companies.
In addition, brain-computer interfaces are at a critical stage of transitioning from laboratory research to industrialization and clinical transformation.
Southwest Securities pointed out that from March to April 2026 is the &#34;breaking out moment&#34; for China's brain-computer interface industry payment policies. China is leading in non-invasive/semi-invasive + rehabilitation/research, with invasive approaches to be followed up in the medium to long term, forming policy + scenario advantages in terms of terminology standards, priority approvals, and medical insurance project funding for brain-computer interfaces. In the medium to long term, domestic semi-invasive ladder medicine, Brain Tiger Technology, Boruikang, and Neuralink's clinical nodes, along with the gradual coverage of domestic medical insurance, will drive growth
Medical Devices ETF China Merchants (159898) tracks the China Securities CSI All Share Medical Apparatus and Instruments Index, with approximately 24% invested in companies with substantial layouts in brain-computer interfaces, providing a good layout advantage in cutting-edge medical technology. This index focuses on the Growth Enterprise Market and the Science and Technology Innovation Board, covering three main areas: medical devices, medical consumables, and in vitro diagnostics. The β quality is pure, able to 100% represent the A-share medical device sector, and may comprehensively layout opportunities for the commercial landing of the brain-computer interface industry

688271

159898

On May 21st, the medical device sector started, with United Imaging Healthcare rising over 12%, and the China Merchants CSI All Share Medical Apparatus and Instruments ETF (159898) rising over 2.5%. The National Medical Products Administration announced that three products entered the innovation channel, promoting innovation in medical devices. It is expected that the industry's performance will stabilize and rebound by 2026, with exports becoming a major growth point. Some companies are expanding into non-medical products, and brain-computer interfaces are transitioning towards industrialization

同壁财经

United Imaging Healthcare

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Hotgen

iRay

ANDON HEALTH

Endovastec

SWS Medical

SINOMED

CHUNLI MEDICAL

Chunli Medical

GUOSEN SECURITIES

GLMS SEC

ZHONGTAI SECURITIES

SHCF

SWSC

Guolian Minsheng Sec

United Imaging Healthcare rose over 12%! Three medical devices entered the innovation channel, and the medical apparatus and instruments ETF China Merchants (159898) rose over 2.5%